International non-proprietary names

The recommended International Non-proprietary Name (rINN) is used throughout the book, except when the terms used are adrenaline and noradrenaline. For further reference, see the British National Formulary. 

Under Directive 2004/27/EC, there are various changes to the information to be included on the product label and certain provisions relating to the product s package leaflet. There is also a new requirement for the name of the medicinal product to be expressed in Braille format on the label. For products containing up to three active substances, the legislation specifies that the international non-proprietary name (INN) must also appear on the labelling. The MAH must also ensure that the package leaflet is made... 

When possible, we have attempted to indicate why fluoiination has been performed, according to the general statements described in the first part of this chapter. In some cases, we have included challenging aspects of syntheses. Concerning the marketed or advanced developed drugs, more references can be found in Chemical Abstracts, under INN names (International Non-proprietary Names). 

In order to give a clear overview, this chapter classically introduces pharmaceuticals according to their respective therapeutic class. Their chemical synthesis is given only when it has a specific interest in fluorine chemistry. The reader will appreciate the marketed names of the cited pharmaceuticals reported under INN names (International Non-proprietary Names) in the appendix. General references about marketed products (or under development) can be found in the Chemical Abstracts by using the INN (italic in the text). 

U.S. Adopted Name Indinavir Sulfate International Non-Proprietary Name Indinavir International Non-Proprietary Name modified Indinavir Sulfate (This nomenclature will be used throughout to designate the sulfate salt (ethanol solvate) unless otherwise indicated.)... 

Table 3 Recommended International Non-proprietary Names (rINNs) and chemical names of the major prostaglandins...

We are also currently experiencing a transitional period during which many established drug names are being changed to recommended international non-proprietary names (rINN) both names are included here, the rINN preceding the older name. 

World Health Organization, International non-proprietary names for pharmaceutical substances (INN) List 84, WHO Drug Inf, 14, 245-280, 2000. 

Drugs have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN) when these are not available, chemical names have been used. In some cases brand names have been used. 

The generic name, the standard being the WHO International Non-proprietary Name, is the first choice of the EMBASE indexers and for combination preparations the brand name is preferred. However, EMBASE allows drugs to be indexed under numerous names, more so than MEDLINE, and even includes the name of the manufacturer if it is in the original article. EMBASE concentrates more on the pharmacological and toxicological aspects of the biomedical literature than MEDLINE. 

Although epinephrine is the recommended International Non-proprietary Name (rINN), there are good reasons why the name adrenahne should be preferred, based on usage, history, etymology, and, most importantly, risk of chnical errors (1). 

Medicinal product purchase intended for the hospital sector is made through international tenders according to procedures of transaction drawn up by the Medicinal Product Purchasing Commission (CAM) and within the framework of a hospital nomenclature enclosing 461 International Non-Proprietary Names (INN), which corresponds to 837 pharmaceuticeil forms (XXIV Congres Medical Maghrebin 1995). 

The usual names such as INN (International Non proprietary Names), INNv (proposed International Nonproprietary Names) and other customary names are given in the indexes. In addition, with the spectra of all pharmaceutical substances (with the exception of complex molecules and polymers) the chemical structural formulas and the relative molecular weights are indicated. Therefore the designation by scientific nomenclature has been dispensed with. 

Gifts may bear no more than the name of a product, its approved name and logo of the company, and the name of the medicinal product, or its recommended international non-proprietary name (or rINN), where this exists, or the trademark, unless they adhere to the requirements for promotional advertising. 

The organiser determines the topics of the event. These should be treated in an objective manner based on the current state of scientific knowledge. In principle, when medicinal products are mentioned in the lectures, they should be referred to with the internationally acknowledged active ingredient description (DCI) or recommended international non-proprietary name (rINN). 

Non-promotional information for patients and the general public Subject to any applicable national laws and regulations, websites may include non-promotional information for patients and the general public on products distributed by the company (including information on their indications, side effects, interactions with other medicines, proper use, reports of clinical research, etc.), provided that such information is balanced, accurate and consistent with the approved summary of product characteristics (SPC). For each product that is discussed, the website must contain full, unedited copies of the current SPC and patient leaflet. These documents should be posted in conjunction with other information about the products or be connected with that discussion by a prominent link advising the reader to consult them. In addition, the website may provide a link to the full, unedited copy of any public assessment report issued by the Committee for Medicinal Products for Human Use or a relevant national competent authority. Brand names should be accompanied by recommended international non-proprietary names (rINNs). 

International Non-proprietary Name (INN) and Japanese Accepted Name (JAN) publications. 

Lipinski et al. used the USAN (United States Adopted Name) and the INN (International Non-proprietary Name) lists to derive a database of compounds that entered phase II studies [33, 37] and therefore should not show major solubility or permeability problems. 

---